Charles River Labs seeks support for merger with WuXi
Facing opposition over its $1.6 billion merger with WuXi Pharmatech, Charles River Laboratories International is wooing support for the deal with a new investor presentation and positive responses from clients. Looking to bolster support for its proposed, $1.6 billion merger with Shanghai-based WuXi PharmaTech (Cayman) Inc. (NYSE:WX), Charles River Laboratories International Inc. (NYSE:CRL) is mounting […]